Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2024-02-14 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-02-14 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 450.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activity Report for the Period to 31 December 2023' and includes detailed operational highlights, clinical trial updates, financial performance overview, and a comprehensive Appendix 4C quarterly cash flow statement. The presence of actual financial data such as cash flows from operating, investing, and financing activities, plus detailed commentary on R&D expenditure, staff costs, and cash balances, indicates this is a substantive financial report for a quarter. The document is about 15,000 characters long, well above the threshold for a brief announcement. It is not merely an announcement of a report or a certification. The document fits the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains substantive financial data and analysis. Therefore, the correct classification is IR. Q4 2023
2024-01-30 English
Application for quotation of securities - AVR 8 pages 30.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Application for quotation of +securities' and details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. It includes specifics such as the number of securities, issue dates, and classifications under ASX codes. There is no financial performance data, management discussion, or earnings information. The document is an announcement related to the listing or quotation of securities on the exchange, specifically related to share issuance due to option exercises. This fits the category of Share Issue/Capital Change (SHA) as it announces new shares being issued and quoted following conversion of options. The document length and content confirm it is not a brief notice but a full announcement of the capital change.
2024-01-24 English
Three ViV Patients Completed under Health Canada SAP 2 pages 190.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 22 January 2024, describing the completion of three valve-in-valve procedures using the DurAVR™ heart valve under Health Canada's Special Access Program. It includes quotes from clinicians and the CEO, background information about the company and its product, and contact details for investor relations. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management changes, no merger or acquisition information, and no mention of report attachments or filings. The content is a corporate announcement about a clinical milestone and product update rather than a financial or regulatory report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-01-21 English
Notification of cessation of securities - AVR 5 pages 26.2KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of certain options (conditional rights to securities) for Anteris Technologies Ltd. It provides specific information about the securities that have ceased, including ASX security codes, reasons for cessation, and dates. The document is a formal announcement to the ASX about changes in the company's issued capital due to securities lapsing. It does not contain financial statements, management discussion, or detailed financial results. It is not an annual or interim report, nor a call transcript or audit report. It is a regulatory announcement about changes in securities status, specifically cessation of securities. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. The document length (5926 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2024-01-10 English
Application for quotation of securities - AVR 8 pages 30.6KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the issuance and quotation of securities resulting from options being exercised or convertible securities being converted. It includes specifics such as the number of securities, issue dates, and classifications under ASX codes. There is no financial performance data, management discussion, or earnings information. The document is an announcement related to the quotation of securities on the ASX, which aligns with announcements about share issues or capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is 7,233 characters, which is substantive and contains detailed information about the securities issued and their quotation application, not merely a brief notice or a report publication announcement.
2024-01-10 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.